BioAtla, Inc. Income Statement
BCAB|2 years of annual SEC 10-K data (FY2021-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
N/A
FY2022
Gross Profit
N/A
FY2022
Operating Income
-$108M
FY2022
Net Income
-$106M
FY2022
Key Data Points
- Altman Z-Score -0.29 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -59.1% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Revenue | - | $300.0K |
| SG&A Expense | $28.8M | $38.4M |
| R&D Expense | $79.3M | $58.3M |
| Operating Income | -$108.1M | -$96.4M |
| Interest Expense | $0 | $3.0K |
| Income Tax | $0 | $0 |
| Net Income | -$106.5M | -$95.4M |
| EPS (Basic) | -$2.76 | - |
| EPS (Diluted) | -$2.76 | -$3.19 |
| Shares Outstanding | 35.8M | 32.2M |
| Operating Margin | - | -32146.7% |
| Profit Margin | - | -31800.7% |